These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 19136484)

  • 1. Patients with peripheral arterial disease in the CHARISMA trial.
    Cacoub PP; Bhatt DL; Steg PG; Topol EJ; Creager MA;
    Eur Heart J; 2009 Jan; 30(2):192-201. PubMed ID: 19136484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial.
    Bhatt DL; Flather MD; Hacke W; Berger PB; Black HR; Boden WE; Cacoub P; Cohen EA; Creager MA; Easton JD; Hamm CW; Hankey GJ; Johnston SC; Mak KH; Mas JL; Montalescot G; Pearson TA; Steg PG; Steinhubl SR; Weber MA; Fabry-Ribaudo L; Hu T; Topol EJ; Fox KA;
    J Am Coll Cardiol; 2007 May; 49(19):1982-8. PubMed ID: 17498584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial.
    Wang TH; Bhatt DL; Fox KA; Steinhubl SR; Brennan DM; Hacke W; Mak KH; Pearson TA; Boden WE; Steg PG; Flather MD; Montalescot G; Topol EJ;
    Eur Heart J; 2007 Sep; 28(18):2200-7. PubMed ID: 17673448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.
    Berger PB; Bhatt DL; Fuster V; Steg PG; Fox KA; Shao M; Brennan DM; Hacke W; Montalescot G; Steinhubl SR; Topol EJ;
    Circulation; 2010 Jun; 121(23):2575-83. PubMed ID: 20516378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of oral anticoagulants in patients with peripheral arterial disease: rationale, design, and baseline characteristics of the Warfarin and Antiplatelet Vascular Evaluation (WAVE) trial, including a meta-analysis of trials.
    WAVE Investigators
    Am Heart J; 2006 Jan; 151(1):1-9. PubMed ID: 16368284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISMA] trial).
    Dasgupta A; Steinhubl SR; Bhatt DL; Berger PB; Shao M; Mak KH; Fox KA; Montalescot G; Weber MA; Haffner SM; Dimas AP; Steg PG; Topol EJ;
    Am J Cardiol; 2009 May; 103(10):1359-63. PubMed ID: 19427428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clopidogrel and aspirin versus aspirin alone for the prevention of stroke in patients with a history of atrial fibrillation: subgroup analysis of the CHARISMA randomized trial.
    Hart RG; Bhatt DL; Hacke W; Fox KA; Hankey GJ; Berger PB; Hu T; Topol EJ;
    Cerebrovasc Dis; 2008; 25(4):344-7. PubMed ID: 18303254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease.
    ; Anand S; Yusuf S; Xie C; Pogue J; Eikelboom J; Budaj A; Sussex B; Liu L; Guzman R; Cina C; Crowell R; Keltai M; Gosselin G
    N Engl J Med; 2007 Jul; 357(3):217-27. PubMed ID: 17634457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: Insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial.
    Aronow HD; Steinhubl SR; Brennan DM; Berger PB; Topol EJ;
    Am Heart J; 2009 Feb; 157(2):369-74. PubMed ID: 19185647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clopidogrel in addition to aspirin reduces one-year major adverse cardiac and cerebrovascular events in unselected patients with non-ST segment elevation myocardial infarction.
    Zeymer U; Gitt AK; Zahn R; Jünger C; Bauer T; Köth O; Heer T; Wienbergen H; Gottwik M; Senges J
    Acute Card Care; 2008; 10(1):43-8. PubMed ID: 17924233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study.
    Jolly SS; Pogue J; Haladyn K; Peters RJ; Fox KA; Avezum A; Gersh BJ; Rupprecht HJ; Yusuf S; Mehta SR
    Eur Heart J; 2009 Apr; 30(8):900-7. PubMed ID: 18819961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overcoming aspirin resistance: increased platelet inhibition with combination aspirin and clopidogrel and high dose aspirin therapy in aspirin resistant patients with peripheral vascular disease.
    Wong S; Morel-Kopp MC; Chen Q; Appleberg M; Ward CM; Lewis DR
    Thromb Haemost; 2006 Jun; 95(6):1042-3. PubMed ID: 16732389
    [No Abstract]   [Full Text] [Related]  

  • 13. Antiplatelet and antithrombotic treatment of patients with peripheral arterial disease.
    Poredos P; Jezovnik MK
    Int Angiol; 2010 Feb; 29(1):20-6. PubMed ID: 20224527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination antiplatelet therapy in patients with peripheral arterial disease: is the best therapy aspirin, clopidogrel, or both?
    Mohler ER
    Catheter Cardiovasc Interv; 2009 Jul; 74 Suppl 1():S1-6. PubMed ID: 19213065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination antiplatelet therapy for secondary stroke prevention: enhanced efficacy or double trouble?
    Usman MH; Notaro LA; Nagarakanti R; Brahin E; Dessain S; Gracely E; Ezekowitz MD
    Am J Cardiol; 2009 Apr; 103(8):1107-12. PubMed ID: 19361598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination therapy with warfarin plus clopidogrel improves outcomes in femoropopliteal bypass surgery patients.
    Monaco M; Di Tommaso L; Pinna GB; Lillo S; Schiavone V; Stassano P
    J Vasc Surg; 2012 Jul; 56(1):96-105. PubMed ID: 22551909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of bleeding complications with omega-3 fatty acids + aspirin + clopidogrel--versus--aspirin + clopidogrel in patients with cardiovascular disease.
    Watson PD; Joy PS; Nkonde C; Hessen SE; Karalis DG
    Am J Cardiol; 2009 Oct; 104(8):1052-4. PubMed ID: 19801023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aspirin plus clopidogrel and risk of infection after coronary artery bypass surgery.
    Blasco-Colmenares E; Perl TM; Guallar E; Baumgartner WA; Conte JV; Alejo D; Pastor-Barriuso R; Sharrett AR; Faraday N
    Arch Intern Med; 2009 Apr; 169(8):788-96. PubMed ID: 19398691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38.
    Wiviott SD; Braunwald E; Angiolillo DJ; Meisel S; Dalby AJ; Verheugt FW; Goodman SG; Corbalan R; Purdy DA; Murphy SA; McCabe CH; Antman EM;
    Circulation; 2008 Oct; 118(16):1626-36. PubMed ID: 18757948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognosis of patients suffering an acute coronary syndrome while already under chronic clopidogrel therapy.
    Bonello L; De Labriolle A; Lemesle G; Steinberg DH; Roy P; Torguson R; Suddath WO; Satler LF; Kent KM; Pichard AD; Waksman R
    Catheter Cardiovasc Interv; 2009 Jun; 73(7):866-70. PubMed ID: 19198009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.